The FDA has issued a Request for Information (RFI) seeking public comment on how to advance the development of FDA botanical drug products — therapeutics derived from plant materials, algae, macroscopic fungi, or combinations thereof intended to diagnose, treat, mitigate, cure, or prevent disease. Published to the Federal Register on September 3, 2026, under Docket No. FDA-2026-N-9550, the action was framed as part of an administration initiative to streamline regulatory pathways and foster medical innovation. The comment period closes November 3, 2026.

What it covers

The RFI solicits feedback across six substantive areas: barriers in botanical research and drug development; innovative approaches to accelerate development; potential updates to FDA guidance documents and other agency resources; quality standards for complex botanical mixtures; appropriate clinical and nonclinical study designs; and the potential use of real-world evidence (RWE) and other scientifically credible data sources in regulatory submissions. To date, four botanical products have received marketing approval through the new drug application (NDA) or biologics license application (BLA) pathways, though certain botanical active ingredients — including psyllium and witch hazel — are already marketed under over-the-counter (OTC) monographs. The RFI follows a recent Reagan-Udall Foundation roundtable on botanical drug development challenges and precedes a joint FDA-European Medicines Agency (EMA) workshop on herbal medicinal and botanical drug product regulation scheduled for September 25, 2026.

Why it matters

The persistent regulatory challenges posed by the inherent complexity and variability of plant-derived materials, including characterization, standardization, and clinical evidence generation. By soliciting input on study design, quality standards, and RWE, the FDA is exploring ways to address persistent development barriers for complex botanical products, including possible updates to guidance and other agency resources. The comment period gives developers, academic researchers, and trade associations an opportunity to influence how FDA approaches future guidance, standards, and development policy for botanical drugs. The upcoming FDA-EMA workshop may also provide indications of where US and European approaches to herbal and botanical medicines overlap or diverge.

What to watch

  • Comment period deadline (November 3, 2026): Comments on study design, quality standards, and use of RWE are likely to be particularly relevant given FDA's emphasis on these issues in the RFI.
  • FDA-EMA joint workshop (September 25, 2026): Workshop outcomes may signal where the two agencies are converging on evidentiary standards and oversight frameworks for herbal and botanical products.
  • Guidance revision timeline: The RFI carries no commitment to a specific rulemaking or guidance update schedule. Follow-on draft guidance publications or program announcements would indicate how the agency intends to act on input received.
  • RWE framework development: FDA's explicit inclusion of RWE as a topic of inquiry aligns with broader agency-wide efforts to expand its use across therapeutic areas; any botanical-specific RWE framework that emerges could have precedent value for other complex or natural-product-derived drug categories.

Source attribution

FDA press announcement — September 3, 2026

Spot something wrong? Report an issue with this article